Advancing the Care of Patients Living with EGPA Through Multidisciplinary, Patient-Focused
Care

Faculty

Michael Wechsler, MD, MMSc (Chair)

Director, The Cohen Family Asthma Institute

Professor

Department of Medicine

Division of Pulmonary, Critical Care & Sleep Medicine

National Jewish Health

Denver, CO

Leonard Calabrese, DO

Professor of Medicine

Cleveland Clinic Lerner College of Medicine

Vice Chair, Department of Rheumatic and Immunologic Diseases

Director, Center for Vasculitis Care and Research

Director, Cleveland Clinic's RJ Fasenmyer Center for Clinical Immunology

Cleveland Clinic

Cleveland, OH

Anisha B. Dua, MD, MPH

Associate Professor,

Fellowship Program Director,
and Director of the Vasculitis Center,
Division of Rheumatology,
Northwestern University Feinberg School of Medicine,
Chicago, Illinois

Program Overview

The comprehensive program provides up-to-date information regarding EGPA—its recognition,
diagnosis, and treatment—and incorporates the patient perspective to raise awareness of
patients’ needs, heighten urgency, and, ultimately, educate on the disease. The program will
explore new insights into the mechanisms of EGPA immunopathogenesis. Additionally, it will
provide health care providers with an update on standard of care treatment options based for
the different EGPA stages. A multidisciplinary approach to care is necessary to achieve optimal
outcomes in EGPA. As such, this activity will provide clinicians with tools to better implement
multidisciplinary, patient-centered approached to care into their clinical practice.

Target Audience

This educational activity is intended for rheumatologists, allergists, immunologists,
pulmonologists, and specialty advance practice clinicians who care for patients with EGPA.

Educational Objectives

  • Summarize the latest EGPA guidelines regarding early diagnosis and initiation of therapy considering the manifold possible presentations of EGPA
  • List the signs and symptoms that may raise the index of suspicion for EGPA
  • Select standard of care treatment and management options for different EGPA stages
  • Explain patient-focused, multidisciplinary management tactics that can be implemented into clinical care to improve care for patients with EGPA

 Disclosures

Disclosures of Relevant Financial Relationships
PACE requires planners, faculty, and others who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.   The faculty reported the following financial relationships or relationships to products or devices they have with ineligible companies:

Michael Wechsler, MD, MMSc
Consultant, Advisor, or Speaker: Amgen, AstraZeneca, Avalo Therapeutics, Boehringer Ingelheim, Cereco, Cohero Health, Cytoreason, Eli Lilly, Equillium, GlaxoSmithKline, Incyte, Kinaset, Novartis, Om Pharma, Phylaxis, Pulmatrix, Rapt Therapeutics, Regeneron, Restorbio, Roche/Genentech, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Teva, Upstream Bio

Leonard Calabrese, DO
Consultant, Advisor, or Speaker: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Galvani, GlaxoSmithKline, Genentech, Janssen, Regeneron, Sanofi/Genzyme, UCB

Anisha Dua, MD, MPH
Consultant, Advisor, or Speaker: AbbVie, Chemocentryx, Novartis, Sanofi

The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The Iridium planners and others have no relevant financial relationship(s) to disclose with ineligible companies.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Acreditation 

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Iridium.  PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PACE designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
Credit Amount: 1.00
Credit Type: AMA
Release: 4/6/2023
Expiration: 4/6/2024
This activity is jointly provided by Partners for Advancing Clinical Education and Iridium Continuing Education.
SUPPORTER ACKNOWLEDGEMENT
This educational activity is supported by an educational grant from GSK.
[email protected]
Copyright © 2023